Syndax Pharmaceuticals, Inc. (SNDX) News
Filter SNDX News Items
SNDX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SNDX News Highlights
- For SNDX, its 30 day story count is now at 9.
- Over the past 18 days, the trend for SNDX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- ASH are the most mentioned tickers in articles about SNDX.
Latest SNDX News From Around the Web
Below are the latest news stories about SYNDAX PHARMACEUTICALS INC that investors may wish to consider to help them evaluate SNDX as an investment opportunity.
With 85% ownership of the shares, Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is heavily dominated by institutional ownersKey Insights Institutions' substantial holdings in Syndax Pharmaceuticals implies that they have significant influence... |
Syndax Announces Closing of Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional SharesSyndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the closing of its previously announced underwritten public offering of 12,432,431 shares of its common stock, which includes the exercise in full of the underwriters' option to purchase 1,621,621 additional shares. The public offering price of each share of common stock was $18.50. The aggregate gross pro |
12 Most Promising Cancer Stocks According to AnalystsIn this piece, we will take a look at the 12 most promising cancer stocks according to analysts. If you want to skip our overview of the latest trends in the cancer treatment sector, then you can take a look at the 5 Most Promising Cancer Stocks According to Analysts. The advent of technology and […] |
Syndax Announces Pricing of $200 Million Public Offering of Common StockSyndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the pricing of an underwritten public offering of 10,810,810 shares of its common stock. The public offering price of each share of common stock is $18.50. The aggregate gross proceeds from this offering are expected to be approximately $200.0 million, before deducting underwriting discounts and commissions and |
Syndax Announces Proposed $150 Million Public Offering of Common StockSyndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it plans to offer and sell, subject to market and other conditions, $150 million of shares of its common stock in an underwritten public offering. Syndax also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in the public offe |
Syndax Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual MeetingSyndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today presented positive data from the protocol-defined pooled analysis of the pivotal AUGMENT-101 trial of revumenib, a first-in-class menin inhibitor, in adult and pediatric patients with relapsed/refractory (R/R) KMT2A-rearranged (KMT2Ar) acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL) at the 65th American Society of Hematology (ASH) Annual Me |
Syndax Announces Positive Data for Revumenib in Patients with Acute Leukemias from the BEAT AML, SAVE AML and AUGMENT-102 Phase 1 Combination TrialsSyndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced data from multiple trials of revumenib in combination with standard of care agents in patients with nucleophosmin mutant (mNPM1) and KMT2A-rearranged (KMT2r) relapsed/refractory (R/R) acute leukemias. Revumenib is the Company's highly selective, oral menin inhibitor. |
Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host DiseaseWILMINGTON, Del. & WALTHAM, Mass., December 10, 2023--Incyte and Syndax Present Additional Data from AGAVE-201 Trial at ASH Plenary Showing Axatilimab Efficacy Including Durable Responses in Chronic GVHD |
12 Most Promising Stocks to Buy According to Hedge FundsIn this article, we will take a look at the 12 most promising stocks to buy according to hedge funds. To see more such companies, go directly to 5 Most Promising Stocks to Buy According to Hedge Funds. Analysts and financial institutions are starting to release their 2024 market outlook reports and predictions and you […] |
Syndax to Host Investor Event to Discuss Axatilimab and Revumenib Data Updates at 65th ASH Annual MeetingSyndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the Company will host an in-person investor event, along with a live webcast, on Monday, December 11, 2023, at 7:00 a.m. PT / 10:00 a.m. ET during the 65th American Society of Hematology (ASH) Annual Meeting in San Diego, California. |